206 related articles for article (PubMed ID: 37345609)
1. Clinical Characterization of HCC/CCA Mixed Cancers in a Population-based Cohort.
Teufel A; Rodriguez I; Winzler C; Kokh D; Ebert MP; Surovtsova I; Morakis P
J Gastrointestin Liver Dis; 2023 Jun; 32(2):190-196. PubMed ID: 37345609
[TBL] [Abstract][Full Text] [Related]
2. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.
Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z
Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787
[No Abstract] [Full Text] [Related]
3. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.
Lee YT; Wang JJ; Luu M; Noureddin M; Nissen NN; Patel TC; Roberts LR; Singal AG; Gores GJ; Yang JD
Hepatology; 2021 Nov; 74(5):2622-2632. PubMed ID: 34114675
[TBL] [Abstract][Full Text] [Related]
5. Combined hepatocellular-cholangiocarcinoma and its mimickers: Diagnostic pitfalls in surgical pathology.
Laohawetwanit T; Lerttanatum N; Wanpiyarat N; Manasilp N; Chaiparnich S
Ann Diagn Pathol; 2021 Aug; 53():151770. PubMed ID: 34147845
[TBL] [Abstract][Full Text] [Related]
6. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
7. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
8. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
Lee HS; Kim MJ; An C
Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
[TBL] [Abstract][Full Text] [Related]
9. Component with abundant immune-related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis.
Yagi N; Suzuki T; Mizuno S; Kojima M; Kudo M; Sugimoto M; Kobayashi S; Gotohda N; Ishii G; Nakatsura T
Cancer Sci; 2022 May; 113(5):1564-1574. PubMed ID: 35226764
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
[TBL] [Abstract][Full Text] [Related]
11. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852
[TBL] [Abstract][Full Text] [Related]
12. Nestin as a diagnostic and prognostic marker for combined hepatocellular-cholangiocarcinoma.
Calderaro J; Di Tommaso L; Maillé P; Beaufrère A; Nguyen CT; Heij L; Gnemmi V; Graham RP; Charlotte F; Chartier S; Wendum D; Vij M; Allende D; Diaz A; Fuster C; Rivière B; Herrero A; Augustin J; Evert K; Calvisi DF; Leow WQ; Leung HHW; Bednarsch J; Boleslawski E; Rela M; Chan AW; Forner A; Reig M; Pujals A; Favre L; Allaire M; Scatton O; Uguen A; Trépo E; Sanchez LO; Chatelain D; Remmelink M; Boulagnon-Rombi C; Bazille C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Kather JN; Gouw ASH; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Nault JC; Laurent A; Amaddeo G; Regnault H; de Martin E; Sempoux C; Navale P; Shinde J; Bacchuwar K; Westerhoff M; Lo RC; Sebbagh M; Guettier C; Lequoy M; Komuta M; Ziol M; Paradis V; Shen J; Caruso S
J Hepatol; 2022 Dec; 77(6):1586-1597. PubMed ID: 35987274
[TBL] [Abstract][Full Text] [Related]
13. Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.
Garancini M; Goffredo P; Pagni F; Romano F; Roman S; Sosa JA; Giardini V
Liver Transpl; 2014 Aug; 20(8):952-9. PubMed ID: 24777610
[TBL] [Abstract][Full Text] [Related]
14. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
Nguyen CT; Caruso S; Maille P; Beaufrère A; Augustin J; Favre L; Pujals A; Boulagnon-Rombi C; Rhaiem R; Amaddeo G; di Tommaso L; Luciani A; Regnault H; Brustia R; Scatton O; Charlotte F; Brochériou I; Sommacale D; Soussan P; Leroy V; Laurent A; Le VK; Ta VT; Trinh HS; Tran TL; Gentien D; Rapinat A; Nault JC; Allaire M; Mulé S; Zucman-Rossi J; Pawlotsky JM; Tournigand C; Lafdil F; Paradis V; Calderaro J
Clin Cancer Res; 2022 Feb; 28(3):540-551. PubMed ID: 34785581
[TBL] [Abstract][Full Text] [Related]
15. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021).
Terai K; Ishigaki K; Kagawa Y; Okada K; Yoshida O; Sakurai N; Heishima T; Asano K
J Am Vet Med Assoc; 2022 Apr; 260(13):1668-1674. PubMed ID: 35482569
[TBL] [Abstract][Full Text] [Related]
16. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
[TBL] [Abstract][Full Text] [Related]
17. Combined hepatocellular-cholangiocarcinoma: An update.
Beaufrère A; Calderaro J; Paradis V
J Hepatol; 2021 May; 74(5):1212-1224. PubMed ID: 33545267
[TBL] [Abstract][Full Text] [Related]
18. Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction.
Xiao Y; Zheng X; Zhou C; Huang P; Wu F; Yang C; Zeng M
Eur Radiol; 2023 Feb; 33(2):1412-1421. PubMed ID: 36112193
[TBL] [Abstract][Full Text] [Related]
19. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Calderaro J; Ghaffari Laleh N; Zeng Q; Maille P; Favre L; Pujals A; Klein C; Bazille C; Heij LR; Uguen A; Luedde T; Di Tommaso L; Beaufrère A; Chatain A; Gastineau D; Nguyen CT; Nguyen-Canh H; Thi KN; Gnemmi V; Graham RP; Charlotte F; Wendum D; Vij M; Allende DS; Aucejo F; Diaz A; Rivière B; Herrero A; Evert K; Calvisi DF; Augustin J; Leow WQ; Leung HHW; Boleslawski E; Rela M; François A; Cha AW; Forner A; Reig M; Allaire M; Scatton O; Chatelain D; Boulagnon-Rombi C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Pawlotsky JM; Zhang X; Luciani A; Mulé S; Laurent A; Amaddeo G; Regnault H; De Martin E; Sempoux C; Navale P; Westerhoff M; Lo RC; Bednarsch J; Gouw A; Guettier C; Lequoy M; Harada K; Sripongpun P; Wetwittayaklang P; Loménie N; Tantipisit J; Kaewdech A; Shen J; Paradis V; Caruso S; Kather JN
Nat Commun; 2023 Dec; 14(1):8290. PubMed ID: 38092727
[TBL] [Abstract][Full Text] [Related]
20. HNF-1β is a More Sensitive and Specific Marker Than C-Reactive Protein for Identifying Biliary Differentiation in Primary Hepatic Carcinomas.
Patil PA; Taddei T; Jain D; Zhang X
Arch Pathol Lab Med; 2022 Jan; 146(2):220-226. PubMed ID: 34086854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
